Not available
Quote | Arbutus Biopharma Corporation (NASDAQ:ABUS)
Last: | $3.78 |
---|---|
Change Percent: | 2.06% |
Open: | $3.8 |
Close: | $3.78 |
High: | $3.8299 |
Low: | $3.67 |
Volume: | 1,255,643 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
News | Arbutus Biopharma Corporation (NASDAQ:ABUS)
2024-07-05 07:01:12 ET Summary Today, we take a deeper look at Arbutus Biopharma Corporation, who is focused on developing better treatments for HBV. The company also is locked in litigation against Covid-19 vaccine makers like Moderna that could eventually deliver substantial ups...
2024-07-05 05:29:10 ET Summary Arbutus Biopharma's three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response. Imdusiran (AB-729) shows promise in Phase 2 trials, potentially leading to a functional cure for chronic hepatitis ...
Message Board Posts | Arbutus Biopharma Corporation (NASDAQ:ABUS)
Subject | By | Source | When |
---|---|---|---|
$ABUS Arbutus Biopharma Corporation | mick | investorshub | 04/30/2023 11:03:50 PM |
Arbutus Biopharma Corporation (Nasdaq: $ABUS), a clinical-stage biopharmaceutical | mick | investorshub | 04/18/2023 8:07:45 PM |
With a median price-to-sales (or "P/S") ratio of | mick | investorshub | 04/18/2023 8:06:48 PM |
$ABUS Arbutus Biopharma Corporation | mick | investorshub | 04/15/2023 6:42:52 PM |
rare form / https://investorshub.advfn.com/Arbutus-Biopharma-Corporation-17838#: | mick | investorshub | 04/15/2023 6:42:33 PM |
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment ...